Author:
Aigner Karl R.,Selak Emir
Publisher
Springer Berlin Heidelberg
Reference20 articles.
1. Ando Masahiko, Okamoto Isamu, Yamamoto Nobuyuki, Takeda Koji, Tamura Kenji, Seto Takashi, Ariyoshi Yutaka, and Fukuoka Masahiro: Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non- Small-Cell Lung Cancer Patients Treated With Gefinitib. J Clin Oncol 24:2549–2556, 2006.
2. Hapani Sanjaykumar, Chu David, Wu Shenhong: Risk of gastrointestinal perforation in patients with cancer treated with Bevacizumab: a meta-analysis. Lancet Oncol 2009;10:559–568.
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899–909, 1995.
4. Soon Yu Yang, Stockler Martin R., Askie Lisa M., and Boyer Michael J.: Duration of Chemotherapy for Advanced Non- Small-Cell Lung Cancer: A Systematic Review and Meta- Analysis of Randomized Trials. J Clin Oncol 27:3277–3283, 2009 by American Society of Clinical Oncology.
5. Aigner KR, Selak E: Isolated Thoracic Perfusion as Induction Chemotherapy for Non-Small-Cell Lung Cancer. Submitted for publication.